In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...

CWA Asset Management Group LLC acquired a new position in Organon & Co. (NYSE:OGN – Free Report) in the third quarter, ...

Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

On Tuesday, Organon & Co (OGN) stock saw a decline, ending the day at $16.46 which represents a decrease of $-0.46 or -2.72% from the prior close of $16.92. The stock opened at $16.74 and touched a ...

Despite announcing strong earnings, Organon & Co.'s ( NYSE:OGN ) stock was sluggish. We did some digging and found ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), reducing the price target to $17.00.

Organon Philippines, a women’s health company, recently unveiled its Her Health Finder, an online tool that aims to empower ...

Organon & Co. ( (OGN)) has released its Q3 earnings. Here is a breakdown of the information Organon & Co. presented to its investors. Organon & Co. is a global healthcare company focused on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On a per-share basis, the Jersey City, New Jersey-based company said it had profit of $1.38. Earnings, adjusted for one-time gains and costs, came to 87 cents per share. The results exceeded Wall ...